Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Atara Biotherapeutics's R&D Expenses for the twelve months ending Sep 30, 2025 was $66.39M, down 61.5% year over year. For fiscal 2025 it was $37.45M, down 75.3% from the year before. Over ten years it grew -1.1% a year on average. The highest annual figure on record is $282.00M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.45M | -75.3% |
| FY2024 | Dec 31, 2024 | $151.48M | -32.6% |
| FY2023 | Dec 31, 2023 | $224.79M | -17.5% |
| FY2022 | Dec 31, 2022 | $272.53M | -3.4% |
| FY2021 | Dec 31, 2021 | $282.00M | +15.3% |
| FY2020 | Dec 31, 2020 | $244.65M | +13.2% |
| FY2019 | Dec 31, 2019 | $216.10M | +29.0% |
| FY2018 | Dec 31, 2018 | $167.46M | +106.2% |
| FY2017 | Dec 31, 2017 | $81.21M | +43.7% |
| FY2016 | Dec 31, 2016 | $56.51M | +35.8% |
| FY2015 | Dec 31, 2015 | $41.62M | +169.4% |
| FY2014 | Dec 31, 2014 | $15.45M | +258.7% |
| FY2013 | Dec 31, 2013 | $4.31M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.10M | -85.0% |
| Q2 FY2026 | Jun 30, 2026 | $1.35M | -95.1% |
| Q1 FY2026 | Mar 31, 2026 | $164.00K | -99.4% |
| Q3 FY2025 | Sep 30, 2025 | $2.93M | -93.3% |
| Q2 FY2025 | Jun 30, 2025 | $7.31M | -78.1% |
| Q1 FY2025 | Mar 31, 2025 | $27.43M | -39.7% |
| Q4 FY2024 | Dec 31, 2024 | $28.72M | -42.1% |
| Q3 FY2024 | Sep 30, 2024 | $43.92M | -22.8% |
| Q2 FY2024 | Jun 30, 2024 | $33.33M | -40.6% |
| Q1 FY2024 | Mar 31, 2024 | $45.51M | -26.8% |
| Q4 FY2023 | Dec 31, 2023 | $49.60M | -20.7% |
| Q3 FY2023 | Sep 30, 2023 | $56.89M | -18.9% |
| Q2 FY2023 | Jun 30, 2023 | $56.14M | -13.5% |
| Q1 FY2023 | Mar 31, 2023 | $62.16M | -17.1% |
| Q4 FY2022 | Dec 31, 2022 | $62.52M | -21.0% |
| Q3 FY2022 | Sep 30, 2022 | $70.16M | -0.3% |
| Q2 FY2022 | Jun 30, 2022 | $64.90M | -5.2% |
| Q1 FY2022 | Mar 31, 2022 | $74.96M | +17.0% |
| Q4 FY2021 | Dec 31, 2021 | $79.13M | +20.7% |
| Q3 FY2021 | Sep 30, 2021 | $70.33M | +17.5% |
| Q2 FY2021 | Jun 30, 2021 | $68.48M | +11.2% |
| Q1 FY2021 | Mar 31, 2021 | $64.06M | +11.1% |
| Q4 FY2020 | Dec 31, 2020 | $65.55M | +6.3% |
| Q3 FY2020 | Sep 30, 2020 | $59.88M | +11.8% |
| Q2 FY2020 | Jun 30, 2020 | $61.56M | +17.8% |
| Q1 FY2020 | Mar 31, 2020 | $57.66M | +18.5% |
| Q4 FY2019 | Dec 31, 2019 | $61.64M | -1.0% |
| Q3 FY2019 | Sep 30, 2019 | $53.54M | +23.5% |
| Q2 FY2019 | Jun 30, 2019 | $52.25M | +56.5% |
| Q1 FY2019 | Mar 31, 2019 | $48.67M | +71.0% |
| Q4 FY2018 | Dec 31, 2018 | $62.26M | +151.3% |
| Q3 FY2018 | Sep 30, 2018 | $43.36M | +110.5% |
| Q2 FY2018 | Jun 30, 2018 | $33.39M | +82.5% |
| Q1 FY2018 | Mar 31, 2018 | $28.46M | +62.2% |
| Q4 FY2017 | Dec 31, 2017 | $24.77M | +83.8% |
| Q3 FY2017 | Sep 30, 2017 | $20.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $18.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.47M | – |
See a number that looks wrong?